Variant report
Variant | esv3384604 |
---|---|
Chromosome Location | chr2:211690495-211709690 |
allele | n/a |
Outlinks | Ensembl   UCSC |
- TF binding region (count:0)
- CpG islands (count:0)
- Chromatin interactive region (count:1)
- LncRNA region (count:0)
- Mature miRNA region (count: 0)
- miRNA target sites (count:0)
No data |
No data |
(count:1 , 50 per page) page:
1
No. | Distal block | Cell Line | Cell type | Cell Stage |
---|---|---|---|---|
1 | chr17:57922098..57924197-chr2:211699892..211701526,2 | MCF-7 | breast: |
No data |
No data |
No data |
No data |
No. | Variant name | Chromosome position | Chromatin state | Related regulatory elements | Target genes | Extended variants | Associated traits |
---|---|---|---|---|---|---|---|
1 | rs2542924 | chr2:211698206-211698207 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
2 | rs545967886 | chr2:211698297-211698298 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
3 | rs35063095 | chr2:211698301-211698302 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
4 | rs531427768 | chr2:211698390-211698391 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
5 | rs6757069 | chr2:211698420-211698421 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
6 | rs568051771 | chr2:211698444-211698445 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
7 | rs527243477 | chr2:211698452-211698453 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
8 | rs547729731 | chr2:211698499-211698500 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
9 | rs142187010 | chr2:211698503-211698504 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
10 | rs369903751 | chr2:211698506-211698507 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
11 | rs4673562 | chr2:211698511-211698512 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
12 | rs182346087 | chr2:211698548-211698549 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
13 | rs375753461 | chr2:211698568-211698569 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
14 | rs548013243 | chr2:211698574-211698575 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
15 | rs538339735 | chr2:211698583-211698584 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
16 | rs34052153 | chr2:211698612-211698613 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
17 | rs554722691 | chr2:211698679-211698680 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
18 | rs574790103 | chr2:211698700-211698701 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
19 | rs540204062 | chr2:211698717-211698718 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
20 | rs373016961 | chr2:211698769-211698770 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
21 | rs56294429 | chr2:211698800-211698801 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
22 | rs566128972 | chr2:211698807-211698808 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
23 | rs577108450 | chr2:211698816-211698817 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
24 | rs546031115 | chr2:211698848-211698849 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
25 | rs563095889 | chr2:211698868-211698869 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
26 | rs531767463 | chr2:211698870-211698871 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
27 | rs541919014 | chr2:211698874-211698875 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
28 | rs73987018 | chr2:211698887-211698888 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
29 | rs527305932 | chr2:211698891-211698892 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
30 | rs151061542 | chr2:211698922-211698923 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
31 | rs564413587 | chr2:211698928-211698929 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
32 | rs140817683 | chr2:211698957-211698958 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
33 | rs549762248 | chr2:211698974-211698975 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
34 | rs144582257 | chr2:211698992-211698993 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
35 | rs7607199 | chr2:211704032-211704033 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
36 | rs2542923 | chr2:211704083-211704084 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
37 | rs145329897 | chr2:211704109-211704110 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
38 | rs572804268 | chr2:211704132-211704133 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
39 | rs181197083 | chr2:211704133-211704134 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
40 | rs539228215 | chr2:211704165-211704166 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
41 | rs552666922 | chr2:211704203-211704204 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
42 | rs76718077 | chr2:211704242-211704243 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
43 | rs533505361 | chr2:211704271-211704272 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
44 | rs537889405 | chr2:211704316-211704317 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
45 | rs554537625 | chr2:211704334-211704335 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
46 | rs1016403 | chr2:211704356-211704357 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
47 | rs534228992 | chr2:211704392-211704393 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
48 | rs114917845 | chr2:211704416-211704417 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
49 | rs577391302 | chr2:211704422-211704423 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
50 | rs546060277 | chr2:211704446-211704447 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
Disease | PMID | Source |
---|---|---|
Ewing''s sarcoma | 21437220 | CNVD |
Glioblastoma multiforme | 21080181 | CNVD |
Medulloblastoma | 21979893 | CNVD |
Ependymoma | 16718352 | CNVD |
Melanoma | 18172304 | CNVD |
Cancer | 16751803 | CNVD |
T-cell prolymphocytic leukemia | 19278963 | CNVD |
Acute lymphoblastic leukemia | 20067559 | CNVD |
Acute lymphoblastic leukemia | 21980252 | CNVD |
Breast cancer | 17603634 | CNVD |
Testicular germ cell tumor | 18059402 | CNVD |
Breast cancer | 16272173 | CNVD |
Ewing''s sarcoma | 17952124 | CNVD |
Cancer | 21637783 | CNVD |
Non-syndromic sensorineural hearing loss | 18471307 | CNVD |
Esophageal squamous carcinoma | 21637470 | CNVD |
Liposarcoma | 21253554 | CNVD |
Endometrial cancer | 22040021 | CNVD |
Breast cancer | 21264507 | CNVD |
Embryonal rhabdomyosarcoma | 16790082 | CNVD |
Autism | 16446308 | CNVD |
Autism | 19401682 | CNVD |
Colorectal cancer | 16272173 | CNVD |
Lung cancer | 18438408 | CNVD |
Prostate cancer | 18632612 | CNVD |
Acute myeloid leukemia | 20729466 | CNVD |
small cell lung cancer | 20016488 | CNVD |
Biliary cancer | 20360734 | CNVD |
Breast cancer | 20360734 | CNVD |
Coronary artery disease | 20360734 | CNVD |
Crohn''s disease | 20360734 | CNVD |
Hypertension | 20360734 | CNVD |
Rheumatoid arthritis | 20360734 | CNVD |
Type 1 diabetes | 20360734 | CNVD |
Type 2 diabetes | 20360734 | CNVD |
Urothelial carcinoma | 21177765 | CNVD |
Hodgkin''s lymphoma | 17606441 | CNVD |
Cervical cancer | 21062161 | CNVD |
Adenoid cystic carcinoma | 18698036 | CNVD |
Non-muscle invasive bladder neoplasm | 19445696 | CNVD |
Non-small cell lung cancer | 21829676 | CNVD |
Autism | 20808228 | CNVD |
Renal cell carcinoma | 18765545 | CNVD |
Ovarian cancer | 19193619 | CNVD |
Non-small cell lung cancer | 18676828 | CNVD |
Oral squamous cell carcinoma | 17134496 | CNVD |
Myofibroblastic sarcoma | 19369631 | CNVD |
Chordoma | 18071362 | CNVD |
Myelofibrosis | 22110671 | CNVD |
Schizophrenia | 18923514 | CNVD |
Schizophrenia | 22241247 | CNVD |
Non-syndromic sensorineural hearing loss | 15273396 | CNVD |
Urothelial cell carcinoma | 18451213 | CNVD |
Developmental delay | 21147756 | CNVD |
Acute lymphoblastic leukemia | 22237106 | CNVD |
Bipolar disorder | 19114987 | CNVD |
No. | Chromosome Location | Chromatin state | Cell line | Tissue |
---|---|---|---|---|
1 | chr2:211698200-211698600 | Enhancers | ES-UCSF4 Cell Line | embryonic stem cell |
2 | chr2:211698200-211699000 | Enhancers | H9 Cell Line | embryonic stem cell |
3 | chr2:211704000-211704400 | Enhancers | H9 Derived Neuronal Progenitor Cultured Cells | ES cell derived |
4 | chr2:211704400-211707400 | Weak transcription | H9 Derived Neuronal Progenitor Cultured Cells | ES cell derived |
5 | chr2:211707200-211707600 | Enhancers | ES-I3 Cell Line | embryonic stem cell |
6 | chr2:211707200-211707600 | Enhancers | iPS DF 6.9 Cell Line | embryonic stem cell |
7 | chr2:211707200-211707800 | Enhancers | H9 Cell Line | embryonic stem cell |
8 | chr2:211707200-211707800 | Enhancers | HUES48 Cell Line | embryonic stem cell |
9 | chr2:211707200-211708000 | Enhancers | H1 Cell Line | embryonic stem cell |
10 | chr2:211707200-211708000 | Enhancers | H9 Derived Neuron Cultured Cells | ES cell derived |
11 | chr2:211707400-211707800 | Enhancers | ES-UCSF4 Cell Line | embryonic stem cell |
12 | chr2:211707400-211707800 | Enhancers | Brain Germinal Matrix | brain |
13 | chr2:211707400-211708000 | Enhancers | iPS-15b Cell Line | embryonic stem cell |
14 | chr2:211707400-211708200 | Enhancers | H9 Derived Neuronal Progenitor Cultured Cells | ES cell derived |
15 | chr2:211707800-211710400 | Weak transcription | HUES48 Cell Line | embryonic stem cell |
16 | chr2:211707800-211712400 | Weak transcription | H9 Cell Line | embryonic stem cell |
17 | chr2:211708000-211711000 | Weak transcription | iPS-15b Cell Line | embryonic stem cell |
18 | chr2:211708200-211708800 | Weak transcription | H9 Derived Neuronal Progenitor Cultured Cells | ES cell derived |
19 | chr2:211708800-211709000 | Enhancers | H9 Derived Neuronal Progenitor Cultured Cells | ES cell derived |